Saturday 30 June 2012

Abbott Vascular - Product Pipeline Analysis

Abbott Vascular Inc. (Abbott Vascular), formerly Perclose, Inc., is a medical device company. It provides a comprehensive portfolio of products for carotid artery disease, coronary artery disease, peripheral vascular disease, structural heart disease and vessel closure. Its key products include Xience V Everolimus Eluting Coronary Stent System, bare metal stents, balloon catheters, guide wires and vessel closure devices. The research and development activity of the company is focused on the development of new products. Also, the company provides physician training, education and easy access online literature on various products as an alternative to printed documents. The company is a division of Abbott Laboratories. Abbott Vascular is headquartered in California, the US.

Abbott Vascular envisages building its position in the marketplace through new product launches, network expansion, internal development, in-licensing of technology and products, acquisitions and strategic alliances. Recently, the company’s Xience Prime and the Xience V Everolimus Eluting Coronary Stent systems have received CE Mark in Europe for the use of dual anti-platelet therapy (DAPT) for at least three months after stent implantation in patients with coronary artery disease. As a part of its strategy Abbott Vascular and St. Jude Medical entered into Choice Alliance, a multi-year joint initiative that provides mutual US customers access to a portfolio of interventional cardiology, cardiac rhythm management, electrophysiology and intravascular imaging and diagnostic technologies.

This report is a source for data, analysis and actionable intelligence on the Abbott Vascular Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Abbott Vascular company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Abbott Vascular pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Abbott Vascular clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84698/abbott-vascular-inc-product-pipeline-analysis.html

Cytograft Tissue Engineering - Product Pipeline Analysis

Cytograft Tissue Engineering, Inc. (CTE) is a medical device company, based in the US. The company develops cell-based solutions to cardiovascular disease. Its product line includes TEBV (Tissue Engineered Blood Vessel), covered stent, patch, percutaneous bypass and valve. CTE’s follow-on products include the LifeGuar patch and the LifeJacket stent-graft. LifeLine is a versatile technology that has the potential to be used for coronary bypass, as a peripheral graft for the prevention of lower limb amputation, or as an arterio-venous shunt for hemodialysis access. It has collaborations with physicians and scientists from Stanford University, the University of Washington, the Minneapolis Heart Institute, the Hope Heart Institute, and the University of Missouri. CTE is headquartered in Novato, California, the US.

This report is a source for data, analysis and actionable intelligence on the Cytograft Tissue Engineering, Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Cytograft Tissue Engineering company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Cytograft Tissue Engineering pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Cytograft Tissue Engineering clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84709/cytograft-tissue-engineering-inc-product-pipeline-analysis.html

ValveXchange - Product Pipeline Analysis

ValveXchange, Inc. (ValveXchange) is a medical device company, based in the US. It develops medical products for cardiovascular markets. The company develops two-part bioprosthetic tissue valves using its patented VXi technology. Its products include surgically implantable valve, transapically implantable valve, exchange tool set, and apical introducer. ValveXchange’s valve exchange procedure can be used in open surgeries, invasive surgical procedures and transcatheter depending on the clinical indication of the patient and physician experience. It has entered in to an option agreement with Dr. Gerard Guiraudon to license his Universal Cardiac Introducer technology. The products offered by the company are approved by FDA. The company has received an equity investment of $3.5m from CryoLife Inc., a tissue processing and medical device company focused on cardiac and vascular surgery. ValveXchange is headquartered in Greenwood Village, Colorado, the US.

This report is a source for data, analysis and actionable intelligence on the ValveXchange portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed ValveXchange company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the ValveXchange pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant ValveXchange clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84707/valvexchange-inc-product-pipeline-analysis.html

Orthox Ltd. - Product Pipeline Analysis

Orthox Ltd (Orthox) is a medical device company, based in the UK. It develops products to regenerate damaged cartilage and bone tissues. The company’s products include FibroFix Meniscus and FibroFix Cartilage. The product FibroFix Meniscus is designed to repair and regenerate the tough, shock absorbing meniscal cartilage in the knee and it replaces the tissue removed in a meniscectomy procedure. Its FibroFix Cartilage is developed to treat the damage done to the articular cartilage in the knee and it enables the surgeon to resurface the articular cartilage defect in the earlier stage. The company markets its products through its brands, FibroFix Meniscus and FibroFix Cartilage. It operates as a subsidiary of Oxford Biomaterials. Orthox is headquartered in Oxfordshire, the UK.

This report is a source for data, analysis and actionable intelligence on the Orthox portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.

Scope

- Detailed Orthox company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Orthox pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each Orthox pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Orthox clinical trials and product patent details, wherever applicable.
- Information on Orthox clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84705/orthox-ltd-product-pipeline-analysis.html

Jemo Spine - Product Pipeline Analysis

Jemo Spine, LLC. (Jemo Spine) is a privately-held medical device company, based in the US. It designs, develops, manufactures and markets orthopedic products for the spine market. The company designs and develops spinal fusion and fixation systems used by the orthopedic surgeons during minimally invasive surgical procedures. Its product portfolio includes classic fusion, dynamic and biologics. Jemo Spine’s classic fusion products are delta, alta and moab. Its dynamic products include smartu, s-flex, spinoflex, spinofix, omega and moab. The company’s biologics consists of BTCP product. Its surgical instruments are made with a stainless steel. The company is ISO 7153/1 certified. Jemo Spine is headquartered in Murray, Utah, the US.

This report is a source for data, analysis and actionable intelligence on the Jemo Spine portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Jemo Spine company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Jemo Spine pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Jemo Spine clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84703/jemo-spine-llc-product-pipeline-analysis.html

Palmaz Scientific - Product Pipeline Analysis

Palmaz Scientific, Inc. (Palmaz) is a medical technology company, based in the US. It research and develops novel technologies in the field of interventional cardiology. The company markets its product through its brand name Palmaz Stent. Palmaz product Palmaz Stent is an expandable intravascular stent that has been created safe, more predictable implantable prosthetic devices, which improve the patient outcomes and quality of life. It conducts research and development operations in Fremont, California. The company has a strong intellectual property portfolio of patented and patent pending thin film metal surface technologies and processing methods. Palmaz is headquartered in Dallas, Texas, the US.

This report is a source for data, analysis and actionable intelligence on the Palmaz Scientific portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Palmaz Scientific company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Palmaz Scientific pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Palmaz Scientific clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84702/palmaz-scientific-inc-product-pipeline-analysis.html

Corentec Co - Product Pipeline Analysis

Corentec Co., Ltd. (Corentec) is a medical equipment company, based in Korea. The company develops and manufactures artificial joints and spinal implant solutions. The company’s products include spinal, hip, knee and the bone substitutes. It offers spine products such as, saddle mounted onto pedicle screws; sleeves to prevent the head from opening wider and bone substitutes include BDP granule, block, porous metal, and TZP or HA products. The company’s knee products include wide range of fixed and mobile bearings. It is certified with ISO 9001:2000 and ISO 13485:2003 for its quality management systems. Corentec is headquartered in Seoul, Korea.

This report is a source for data, analysis and actionable intelligence on the Corentec Co. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Corentec company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Corentec pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Corentec clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84700/corentec-co-ltd-product-pipeline-analysis.html

Akonni Biosystems - Product Pipeline Analysis

Akonni Biosystems Inc (Akonni Biosystems) is a diagnostics company based in the US. The company develops, manufactures, and markets integrated molecular diagnostic systems. It provides products for markets such as, clinical and life science research markets. The products of the company include, nucleic acid extraction kits, MDx tests and instruments and software. Akonni trudiagnosis systems of Akonni Biosystems which is provided for clinical markets enables rapid and affordable testing for a variety of molecular markers associated with human diseases on a gel-drop microarray platform. Akonni TruTip Kits provided for life science research markets provides life science research and molecular laboratories with an affordable, rapid and robust means of extracting nucleic acids. Akonni Biosystems is headquartered in Frederick, Maryland, the US.

This report is a source for data, analysis and actionable intelligence on the Akonni Biosystems Inc portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Akonni Biosystems company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Akonni Biosystems pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Akonni Biosystems clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84696/akonni-biosystems-inc-product-pipeline-analysis.html

Lenstec - Product Pipeline Analysis

Lenstec, Inc. (Lenstec) is a medical device company, based in the US. It designs, manufactures and distributes a wide range of intraocular lens implants and lens injection systems. The company’s products include softec1, softec HD, softec HDY, tetraflex, tetraflex HD, other acrylic lenses, PMMA lenses and surgical support products. It serves ophthalmic surgical markets in the US and internationally. The company’s surgical support products include pre-loaded injectors, viscoelastics and capsular tension rings. Lenstec’s products currently marketed in more than 60 countries. The company was incorporated in 1992. Lenstec is headquartered in Saint Petersburg, Florida, the US.

This report is a source for data, analysis and actionable intelligence on the Lenstec portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Lenstec company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Lenstec pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Lenstec clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84694/lenstec-inc-product-pipeline-analysis.html

The Binding Site - Product Pipeline Analysis

The Binding Site Limited (The Binding Site) is a privately-held medical device company, based in the UK. It develops, manufactures and markets immunodiagnostic assays for the in vitro diagnostic market. The company’s product portfolio includes freelite, hevylite, instrumentation, vaccine response elisa, immnoglobulins & subclasses, complement, other plasma protein assays, rid kits-animal proteins, and antisera, antigens and reagents. Its Quality management system is certified according to ISO 9001:2008 and ISO 13485:2003. The Binding Site’s operations are concentrated in France, Spain, Germany, Canada, Ireland and Austria. It distributes its products through a distribution network in around 62 countries across the world. The company has launched a new clinical trial Hevylite to analyze immunoglobulin heavy chain/light chain (HLC) pairs. It operates as a subsidiary of the The Binding Site Group Ltd. The Binding Site is headquartered in Birmingham, England, the UK.

This report is a source for data, analysis and actionable intelligence on the The Binding Site Limited portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed The Binding Site company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the The Binding Site pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant The Binding Site clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84692/the-binding-site-limited-product-pipeline-analysis.html

Friday 29 June 2012

Rontis - Product Pipeline Analysis

Rontis AG (Rontis) is a medical device company based in Switzerland. The company focuses on research, development, manufacturing and distributing medical devices for interventional cardiology and interventional radiology. It produces interventional cardiology and radiology, anesthesiology, urology, liquid administration and nephrology products. The company’s products include drug eluting stents for cardiology; dilatation catheter for radioligy; flow regulator line, flow extension line and lock fitting cap for liquid administration; nelaton catheter for urology; levin tubes and suction catheters for anesthesiology; extracorporeal bloodline circuits, sn-y line adaptor and drainage bag for nephrology. It supplies its products to OEM manufacturers. Rontis is headquartered in Bahnhofstrasse, Switzerland.

This report is a source for data, analysis and actionable intelligence on the RONTIS AG portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.
Scope

- Detailed RONTIS AG company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the RONTIS AG pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant RONTIS AG clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84640/rontis-ag-product-pipeline-analysis.html

Degradable Solutions - Product Pipeline Analysis

Degradable Solutions AG (Degradable Solutions) is a medical device company, based in Switzerland. The company designs, develops and manufactures degradable medical implants. It offers synthetic bone grafts, tissue fixation implants and porous resorbable foams. The company provides services such as manufacturing services, assembling and packaging, analytics logistics. The company OEM categories include resorbable tissue fixation, calcium phosphates, fibres, foams, films, coatings, coloring, assemblies, micro parts, x-ray markers, compounds and sterilization of resorbable implants. Its clients include medical and pharmaceutical companies throughout the world. Degradable Solutions operates in collaboration with medical companies, research institutes and surgeons. It was founded in 1999. Degradable Solutions is headquartered in Schlieren, Switzerland.

This report is a source for data, analysis and actionable intelligence on the Degradable Solutions portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Degradable Solutions company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Degradable Solutions pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Degradable Solutions clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84628/degradable-solutions-ag-product-pipeline-analysis.html

DesignWise Medical- Product Pipeline Analysis

Design Wise Medical Inc. (Design Wise Medical) is a non-profit pediatric device company, based in the US. The company provides medical needs for children and applicable technology. Its product portfolio includes OPOD system, closed-loop neonatal oxygen control, peripheral vein locator, self-contained nebulizer system and diabetes management tools for children. Design Wise Medical provides service such as solution development and education. It identify the unmet pediatric needs collaborates with health institutions namely, pediatric hospitals, disease-focused groups, parent advocacy groups. The company enters into agreements and collaborations with partners for the manufacturing, marketing and distribution of its products and services. Design Wise Medical is headquartered in Minneapolis, Minnesota, the US.

This report is a source for data, analysis and actionable intelligence on the DesignWise Medical portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed DesignWise Medical company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the DesignWise Medical pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant DesignWise Medical clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84638/designwise-medical-inc-product-pipeline-analysis.html

IQuum - Product Pipeline Analysis

IQuum, Inc. (IQuum) is a medical device service provider company, based in the US. It develops and offers biological sample testing technology for the bioassay market. The company’s products and technology include lait analyzer, flr a/b assay, 2009 H1N1 assay, liat workstation, assay pipeline, lab-in-a-tube technology, technical support and MSDS. Its proprietary lab-in-a-tube technology will enable the less experienced personnel to perform more sophisticated biological sample testing in a less expensive setting with speed. The company is also developing a pipeline of liat assays for infectious disease and genetic testing. It serves hospitals, clinics, physician offices, and emergency responders. IQuum is headquartered in Marlborough, Massachusetts, the US.

This report is a source for data, analysis and actionable intelligence on the IQuum portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed IQuum company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the IQuum pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant IQuum clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84635/iquum-inc-product-pipeline-analysis.html

Glycominds - Product Pipeline Analysis

Glycominds Ltd. (GML), a medical device provider, based in Israel. It develops and commercializes autoimmune and chronic inflammatory disease management tools and services with a distinctive focus on the Multiple Sclerosis market. The company’s products include gMS DX, gMS Pro EDSS and IBDX. Its gMS Dx test provides clinically valuable information clinicians can use to help make decisions about the likelihood of having Multiple Sclerosis. Glycominds’ technology platform assesses the immune response by measuring the level of antibody biomarkers against glycans. The company’s gMS tests help physicians identify patients who have Multiple Sclerosis and which of these patients are likely to progress towards disability. GML is headquartered in Lod, Israel.

This report is a source for data, analysis and actionable intelligence on the Glycominds portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Glycominds company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Glycominds pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Glycominds clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84632/glycominds-ltd-product-pipeline-analysis.html

ARK Diagnostics - Product Pipeline Analysis

ARK Diagnostics Inc. (ARK Diagnostics) is a medical equipment company, based in the US. The company designs, manufactures and distributes vitro diagnostic products. It provides products for epilepsy and pain management, cancer, veterinary, and HIV or AIDS. The company proprietary assays measurements caters clinicians in guiding dosing decisions for safe, effective, and personalized drug therapy and there by improve outcomes, reduce toxicity, and lower healthcare costs. It is partners with industries that market instrument platforms; leaders in IVD reagent manufacturing; major reference laboratories and distributors. The company is highly regarded homogeneous enzyme immunoassay technology is adaptable to a wide variety of automated clinical chemistry analyzers. Its products are distributed through its brand ARK. ARK Diagnostics is headquartered in Sunnyvale, California, the US.

This report is a source for data, analysis and actionable intelligence on the ARK Diagnostics portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed ARK Diagnostics company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the ARK Diagnostics pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant ARK Diagnostics clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84630/ark-diagnostics-inc-product-pipeline-analysis.html

NanoIVD - Product Pipeline Analysis

NanoIVD, Inc. (Nano) is a medical device company based in the US. The company researches, develops, and commercializes blood-based tests for cancer-recurrence monitoring, treatment-effectiveness monitoring, and personalized molecular cancer profiling for therapeutic selection. It also owns an algorithm for cancer biomarker selection and proprietary nanowire field-effect-transistor (NW-FET) chip technology for label-free and real-time diagnostic testing. Nano’s biosensor chip is embedded in a disposable test cartridge, and can detect pico and femto grams per milliliter of proteins and nucleic acids in less than 15 minutes. The company is partnered with the companies such as, Cedars Sinai Medical Center, Beverly Hills Cancer Center, California NanoSystems Institute, Electrical Engineering and Kavli Nanoscience Institute. Nano is headquartered in Los Angeles, California, the US.

This report is a source for data, analysis and actionable intelligence on the NanoIVD portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed NanoIVD company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the NanoIVD pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant NanoIVD clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84625/nanoivd-inc-product-pipeline-analysis.html

Biotrin International - Product Pipeline Analysis

Biotrin International (Biotrin) is a medical device company, based in Ireland. The company provides novel and proprietary tests for the clinician and research scientist. It operates through product segments such as Parvovirus B19, Herpes Virus, Respiratory Virus, Hantavirus and Approved by FDA. Biotrin operates through business units includes infectious disease unit and biomarkers unit. Infectious disease unit provides test for the detection of emerging viral diseases. Biomarkers unit provide test to assess organ and tissue damage. The company distributes its products in Argentina, Australia, Austria, Belgium, Brazil, Canada, Chile, China, Cyprus, Czech Republic, Denmark, Egypt, Estonia and the US among others. Biotrin is headquartered in Dublin, Ireland.

This report is a source for data, analysis and actionable intelligence on the Biotrin International portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Biotrin International company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Biotrin International pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Biotrin International clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84622/biotrin-international-product-pipeline-analysis.html

Axela - Product Pipeline Analysis

Axela Inc. (Axela) is medical equipment company, based in Canada. It develops products for protein detection, characterization and monitoring products used in clinical research, health research and life science. Its products include dotLab mX system, panelPlus products, dot-Avidin products, dot-Rready products, dot-Covalent products and spare parts. The company provides services such as, technical and application support, on-site and in-house training, extended warranty, service and maintenance contracts, and custom application development services. It enables the real-time detection and quantization of protein binding events in complex media. The company operates though its distributors in the US and Canada with a European Sales office in Netherlands. The company distributes its products through its brands, dotLab mX, panelPlus, dot-Avidin, dot-Ready and dot-Covalent. Axela is headquartered in Ontario, Canada.

This report is a source for data, analysis and actionable intelligence on the Axela Inc. portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Axela company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Axela pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Axela clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84619/axela-inc-product-pipeline-analysis.html

Vascular Closure Systems - Product Pipeline Analysis

Vascular Closure Systems, Inc (VCS) is a medical device company, based in the US. The company develops and commercializes vascular access closure technology for the interventional cardiology market. It develops its medical device based on the intellectual property provided by the CardioVascular Technologies, Inc. Its Intellectual Property (IP) covers more than four different types of sealing methods such as bioabsorbable plug, RF thermal closure, bioabsorbable tubular plug, and self-closing nitinol clip. The Company has entered into an agreement for licensing, manufacturing and distribution of its products in Australia, India, Japan, Philippines, Korea, Malaysia, China, New Zealand, Thailand Singapore, and Taiwan. VCS is headquartered in Livermore, California, the US.

This report is a source for data, analysis and actionable intelligence on the Vascular Closure Systems portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Vascular Closure Systems company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Vascular Closure Systems pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Vascular Closure Systems clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84616/vascular-closure-systems-inc-product-pipeline-analysis.html

Thursday 28 June 2012

Aperion Biologics - Product Pipeline Analysis

Aperion Biologics Corporation (Aperion Biologics) is a medical device company, based in the US. The company has developed and patented a technique to make animal-tissues usable for human applications without causing rejection. It develops and commercializes tissue engineered products for surgical reconstruction of joints and soft tissue. The company’s products include ligament reconstruction instruments based upon bone patellar tendon bone construct, soft tissue tendon construct, and bone tendon construct. Its products support treatment of orthopedic ligaments, bone, cartilage, meniscus, cardiovascular valves/vessels, and soft tissue augmentation/repair applications, as they used to humanize and sterilize animal tissues. The company has 25 issued patents. Aperion Biologics is headquartered in San Antonio, Texas, the US.

This report is a source for data, analysis and actionable intelligence on the Aperion Biologics portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Aperion Biologics company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Aperion Biologics pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Aperion Biologics clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84584/aperion-biologics-corporation-product-pipeline-analysis.html

Rayner Intraocular Lenses - Product Pipeline Analysis

Rayner Intraocular Lenses Limited (Rayner) is a medical device company, based in the UK. The company manufactures intra ocular lens (IOL). Its products include Sulcoflex which includes Sulcoflex Aspheric, Sulcoflex Toric and Sulcoflex Multifocal; Multifocal which includes M-flex, M-flex T and Sulcoflex multifocul; Toric which includes T-flex, M-flex T and Sulcoflex toric; Spherical which includes C-flex and Superflex; Aspheric which includes C-flex, Superflex and Sulcoflex; PMMA Intraocular Lenses. It also provides web based toric calculator and ordering system namely Raytrace. The company operates as a subsidiary of Rayner & Keeler Ltd. Rayner is headquartered in East Sussex, the UK.

This report is a source for data, analysis and actionable intelligence on the Rayner Intraocular Lenses portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Rayner Intraocular Lenses company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all Rayner Intraocular Lenses the pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Rayner Intraocular Lenses clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84580/rayner-intraocular-lenses-limited-product-pipeline-analysis.html

Innocoll Technologies - Product Pipeline Analysis

Innocoll Technologies Ltd (Innocoll Technologies) is a medical device company, based in Ireland. The company develops and markets drug delivery devices for the pharmaceutical and medical markets. Its product pipeline includes cogenzia, xaracoll, gentamicin surgical implant, procoll, durieva. The company’s approve products include gentamicin surgical implant, collaguard adhesion barrier, zorprevasurgical haemostat, collacare family, collexa, lidocoll, innocoll dental. Its products are developed using its technologies namely CollaRx and Liquicoll. Innocoll Technologies products are used in a variety of medical applications such as preventing surgical adhesions in the treatment of post-operative or post-traumatic pain or inflammation and treating deep wounds such as ulcers, burns and acute trauma injuries. Its partners include Baxter, EUSA pharma, Merus labs, curesys, KMA, Pioneer Pharma. Innocoll Technologies is headquartered in Roscommon, Ireland.

This report is a source for data, analysis and actionable intelligence on the Innocoll Technologies portfolio of pipeline products. The report provides detailed analysis on each pipeline product with information on the indication, the development stage, trial phase, product milestones, pipeline territory, estimated approval date, and estimated launch date.

Each pipeline product is profiled to cover information on product description, function, technology, indication, and application. The report is also supplemented with a detailed company profile and information on clinical trials, wherever applicable.

Scope

- Detailed Innocoll Technologies company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments.
- Detailed coverage on all the Innocoll Technologies pipeline products, by equipment type, by therapy area, by development stage, and by trial phase.
- Information on product milestones and pipeline territory for each product, the estimated approval date, and estimated launch date.
- Profile of each pipeline product with additional information on product description, function, technology, indication(s), and application.
- Data on relevant Innocoll Technologies clinical trials and product patent details, wherever applicable.
- Information on clinical trial, wherever applicable, is supplemented with information on trial phase, trial status, trial objective, trial design, target patients, unique physician identifier, primary point, secondary point, acronym, participants inclusion, participants exclusion, interventions, trial results, trial start date, trial end date, study type, trial site, trial funding, age eligibility, and gender eligibility.

Reasons to Buy

- Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape globally.
- Design and develop your product development, marketing and sales strategies.
- Exploit M&A opportunities by identifying market players with the most innovative pipeline.
- Develop market-entry and market expansion strategies.
- Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return.
- Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Develop competition strategies by identifying the status and likely launch of your competitors’ pipeline products through review of the clinical trials, stage and phase of development, etc.
- Which are the next high-value products that your competitor would add in its portfolio? – identify, understand and capitalize.

To view the detailed table of contents for this report please visit: http://www.reportstack.com/product/84578/innocoll-technologies-ltd-product-pipeline-analysis.html